Discovery of [alpha]-amylase and [alpha]-glucosidase dual inhibitors from NPASS database for management of Type 2 Diabetes Mellitus: A chemoinformatic approach

Postprandial hyperglycemia, typical manifestation of Type 2 Diabetes Mellitus (T.sub.2 DM), is associated with notable global morbidity and mortality. Preventing the advancement of this condition by delaying the rate of glucose absorption through inhibition of [alpha]-amylase and [alpha]-glucosidase...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:PloS one 2024-11, Vol.19 (11), p.e0313758
Hauptverfasser: Ndarawit, Wilberforce, Ochieng, Charles Otieno, Angwenyi, David, Cruz, Jorddy N, Santos, Cleydson B. R, Kimani, Njogu M
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue 11
container_start_page e0313758
container_title PloS one
container_volume 19
creator Ndarawit, Wilberforce
Ochieng, Charles Otieno
Angwenyi, David
Cruz, Jorddy N
Santos, Cleydson B. R
Kimani, Njogu M
description Postprandial hyperglycemia, typical manifestation of Type 2 Diabetes Mellitus (T.sub.2 DM), is associated with notable global morbidity and mortality. Preventing the advancement of this condition by delaying the rate of glucose absorption through inhibition of [alpha]-amylase and [alpha]-glucosidase enzymatic activities is of utmost importance. Finding a safe antidiabetic drug is essential since those that are currently on the market have drawbacks like unpleasant side effects. The current study utilized computer-aided drug design (CADD), as a quick and affordable method to find a substitute drug template that can be used to control postprandial hyperglycemia by modulating the activity of [alpha]-amylase and [alpha]-glucosidase enzymes. The Natural Products Activity and Species database (NPASS) (30,926 compounds) was screened in silico, with a focus on evaluating drug-likeness, toxicity profiles and ability to bind on a target protein. Two molecules NPC204580 (Chrotacumine C) and NPC137813 (1-O-(2-Methoxy-4-Acetylphenyl)-6-O-(E-Cinnamoyl)-Beta-D-Glucopyranoside) were identified as potential dual inhibitors for [alpha]-amylase and [alpha]-glucosidase with free binding energies of -14.46 kcal/mol and -12.58 kcal/mol for [alpha]-amylase, and -8.42 kcal/mol and -8.76 kcal/mol for [alpha]-glucosidase, respectively. The molecules showed ionic, H-bonding and hydrophobic interactions with critical amino acid residues of both enzymes. Moreover, 100 ns molecular dynamic simulations showed that both molecules are stable on the receptors' active sites based on root mean square deviation (RMSD), root mean square fluctuation (RMSF), and the Generalized Born surface area (GBSA) energy calculated. The two compounds are thus promising therapeutic agents for T.sub.2 DM that merit further investigation due to their excellent binding energies, encouraging pharmacokinetics, toxicity profiles, and stability as demonstrated in simulated studies.
doi_str_mv 10.1371/journal.pone.0313758
format Article
fullrecord <record><control><sourceid>gale</sourceid><recordid>TN_cdi_gale_infotracmisc_A816058701</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A816058701</galeid><sourcerecordid>A816058701</sourcerecordid><originalsourceid>FETCH-LOGICAL-g1661-5d6ce5d39010f975fdd41c4a372df2ac8e52c368d677879ba9e181fa2ad4744a3</originalsourceid><addsrcrecordid>eNqN0NFq2zAUBmAzWlja9Q16ISgUeuFUsmPZ7l1It7bQLaXpdjNGOJGObAXZMpY8lqfpq1ahpSSwi6ILiZ_vP4gTRaeMjlmas8u1HfoWzLizLY5pGrKs-BSNWJkmMU9oerDz_hwdObemNEsLzkfR87V2wv7FfkOsIr_BdDX8iaHZGHBIoJXvWWUGYZ2W21wOYIhua73S3vaOqN425MfDdLEgEjystkbZnjTQQoUNtn47_WnTIUnItYYVenTkOxqj_eCuyJSIGhur21BqwGtBoOt6C6L-Eh0qMA5P3u7j6Oe3r0-z2_h-fnM3m97HFeOcxZnkAjOZlpRRVeaZknLCxATSPJEqAVFgloiUF5LneZGXKyiRFUxBAnKST4I7js5e51ZgcLn9iO9BNGE5y2nBOM2KnLKgxv9R4UhstAjbVzrke4WLvUIwHv_5CgbnlneLx4_b-a99e75jawTja2fN4LVt3S58AUWVqJc</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Discovery of [alpha]-amylase and [alpha]-glucosidase dual inhibitors from NPASS database for management of Type 2 Diabetes Mellitus: A chemoinformatic approach</title><source>DOAJ Directory of Open Access Journals</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><source>Free Full-Text Journals in Chemistry</source><source>Public Library of Science (PLoS)</source><creator>Ndarawit, Wilberforce ; Ochieng, Charles Otieno ; Angwenyi, David ; Cruz, Jorddy N ; Santos, Cleydson B. R ; Kimani, Njogu M</creator><creatorcontrib>Ndarawit, Wilberforce ; Ochieng, Charles Otieno ; Angwenyi, David ; Cruz, Jorddy N ; Santos, Cleydson B. R ; Kimani, Njogu M</creatorcontrib><description>Postprandial hyperglycemia, typical manifestation of Type 2 Diabetes Mellitus (T.sub.2 DM), is associated with notable global morbidity and mortality. Preventing the advancement of this condition by delaying the rate of glucose absorption through inhibition of [alpha]-amylase and [alpha]-glucosidase enzymatic activities is of utmost importance. Finding a safe antidiabetic drug is essential since those that are currently on the market have drawbacks like unpleasant side effects. The current study utilized computer-aided drug design (CADD), as a quick and affordable method to find a substitute drug template that can be used to control postprandial hyperglycemia by modulating the activity of [alpha]-amylase and [alpha]-glucosidase enzymes. The Natural Products Activity and Species database (NPASS) (30,926 compounds) was screened in silico, with a focus on evaluating drug-likeness, toxicity profiles and ability to bind on a target protein. Two molecules NPC204580 (Chrotacumine C) and NPC137813 (1-O-(2-Methoxy-4-Acetylphenyl)-6-O-(E-Cinnamoyl)-Beta-D-Glucopyranoside) were identified as potential dual inhibitors for [alpha]-amylase and [alpha]-glucosidase with free binding energies of -14.46 kcal/mol and -12.58 kcal/mol for [alpha]-amylase, and -8.42 kcal/mol and -8.76 kcal/mol for [alpha]-glucosidase, respectively. The molecules showed ionic, H-bonding and hydrophobic interactions with critical amino acid residues of both enzymes. Moreover, 100 ns molecular dynamic simulations showed that both molecules are stable on the receptors' active sites based on root mean square deviation (RMSD), root mean square fluctuation (RMSF), and the Generalized Born surface area (GBSA) energy calculated. The two compounds are thus promising therapeutic agents for T.sub.2 DM that merit further investigation due to their excellent binding energies, encouraging pharmacokinetics, toxicity profiles, and stability as demonstrated in simulated studies.</description><identifier>ISSN: 1932-6203</identifier><identifier>EISSN: 1932-6203</identifier><identifier>DOI: 10.1371/journal.pone.0313758</identifier><language>eng</language><publisher>Public Library of Science</publisher><subject>Amino acids ; Amylases ; Biological products ; Care and treatment ; Dextrose ; Diabetes therapy ; Diagnosis ; Force and energy ; Glucose ; Health aspects ; Hydrogen bonding ; Hyperglycemia ; Molecular dynamics ; Properties ; Protein binding ; Type 2 diabetes</subject><ispartof>PloS one, 2024-11, Vol.19 (11), p.e0313758</ispartof><rights>COPYRIGHT 2024 Public Library of Science</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,860,27901,27902</link.rule.ids></links><search><creatorcontrib>Ndarawit, Wilberforce</creatorcontrib><creatorcontrib>Ochieng, Charles Otieno</creatorcontrib><creatorcontrib>Angwenyi, David</creatorcontrib><creatorcontrib>Cruz, Jorddy N</creatorcontrib><creatorcontrib>Santos, Cleydson B. R</creatorcontrib><creatorcontrib>Kimani, Njogu M</creatorcontrib><title>Discovery of [alpha]-amylase and [alpha]-glucosidase dual inhibitors from NPASS database for management of Type 2 Diabetes Mellitus: A chemoinformatic approach</title><title>PloS one</title><description>Postprandial hyperglycemia, typical manifestation of Type 2 Diabetes Mellitus (T.sub.2 DM), is associated with notable global morbidity and mortality. Preventing the advancement of this condition by delaying the rate of glucose absorption through inhibition of [alpha]-amylase and [alpha]-glucosidase enzymatic activities is of utmost importance. Finding a safe antidiabetic drug is essential since those that are currently on the market have drawbacks like unpleasant side effects. The current study utilized computer-aided drug design (CADD), as a quick and affordable method to find a substitute drug template that can be used to control postprandial hyperglycemia by modulating the activity of [alpha]-amylase and [alpha]-glucosidase enzymes. The Natural Products Activity and Species database (NPASS) (30,926 compounds) was screened in silico, with a focus on evaluating drug-likeness, toxicity profiles and ability to bind on a target protein. Two molecules NPC204580 (Chrotacumine C) and NPC137813 (1-O-(2-Methoxy-4-Acetylphenyl)-6-O-(E-Cinnamoyl)-Beta-D-Glucopyranoside) were identified as potential dual inhibitors for [alpha]-amylase and [alpha]-glucosidase with free binding energies of -14.46 kcal/mol and -12.58 kcal/mol for [alpha]-amylase, and -8.42 kcal/mol and -8.76 kcal/mol for [alpha]-glucosidase, respectively. The molecules showed ionic, H-bonding and hydrophobic interactions with critical amino acid residues of both enzymes. Moreover, 100 ns molecular dynamic simulations showed that both molecules are stable on the receptors' active sites based on root mean square deviation (RMSD), root mean square fluctuation (RMSF), and the Generalized Born surface area (GBSA) energy calculated. The two compounds are thus promising therapeutic agents for T.sub.2 DM that merit further investigation due to their excellent binding energies, encouraging pharmacokinetics, toxicity profiles, and stability as demonstrated in simulated studies.</description><subject>Amino acids</subject><subject>Amylases</subject><subject>Biological products</subject><subject>Care and treatment</subject><subject>Dextrose</subject><subject>Diabetes therapy</subject><subject>Diagnosis</subject><subject>Force and energy</subject><subject>Glucose</subject><subject>Health aspects</subject><subject>Hydrogen bonding</subject><subject>Hyperglycemia</subject><subject>Molecular dynamics</subject><subject>Properties</subject><subject>Protein binding</subject><subject>Type 2 diabetes</subject><issn>1932-6203</issn><issn>1932-6203</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><recordid>eNqN0NFq2zAUBmAzWlja9Q16ISgUeuFUsmPZ7l1It7bQLaXpdjNGOJGObAXZMpY8lqfpq1ahpSSwi6ILiZ_vP4gTRaeMjlmas8u1HfoWzLizLY5pGrKs-BSNWJkmMU9oerDz_hwdObemNEsLzkfR87V2wv7FfkOsIr_BdDX8iaHZGHBIoJXvWWUGYZ2W21wOYIhua73S3vaOqN425MfDdLEgEjystkbZnjTQQoUNtn47_WnTIUnItYYVenTkOxqj_eCuyJSIGhur21BqwGtBoOt6C6L-Eh0qMA5P3u7j6Oe3r0-z2_h-fnM3m97HFeOcxZnkAjOZlpRRVeaZknLCxATSPJEqAVFgloiUF5LneZGXKyiRFUxBAnKST4I7js5e51ZgcLn9iO9BNGE5y2nBOM2KnLKgxv9R4UhstAjbVzrke4WLvUIwHv_5CgbnlneLx4_b-a99e75jawTja2fN4LVt3S58AUWVqJc</recordid><startdate>20241114</startdate><enddate>20241114</enddate><creator>Ndarawit, Wilberforce</creator><creator>Ochieng, Charles Otieno</creator><creator>Angwenyi, David</creator><creator>Cruz, Jorddy N</creator><creator>Santos, Cleydson B. R</creator><creator>Kimani, Njogu M</creator><general>Public Library of Science</general><scope>IOV</scope><scope>ISR</scope></search><sort><creationdate>20241114</creationdate><title>Discovery of [alpha]-amylase and [alpha]-glucosidase dual inhibitors from NPASS database for management of Type 2 Diabetes Mellitus: A chemoinformatic approach</title><author>Ndarawit, Wilberforce ; Ochieng, Charles Otieno ; Angwenyi, David ; Cruz, Jorddy N ; Santos, Cleydson B. R ; Kimani, Njogu M</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-g1661-5d6ce5d39010f975fdd41c4a372df2ac8e52c368d677879ba9e181fa2ad4744a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Amino acids</topic><topic>Amylases</topic><topic>Biological products</topic><topic>Care and treatment</topic><topic>Dextrose</topic><topic>Diabetes therapy</topic><topic>Diagnosis</topic><topic>Force and energy</topic><topic>Glucose</topic><topic>Health aspects</topic><topic>Hydrogen bonding</topic><topic>Hyperglycemia</topic><topic>Molecular dynamics</topic><topic>Properties</topic><topic>Protein binding</topic><topic>Type 2 diabetes</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ndarawit, Wilberforce</creatorcontrib><creatorcontrib>Ochieng, Charles Otieno</creatorcontrib><creatorcontrib>Angwenyi, David</creatorcontrib><creatorcontrib>Cruz, Jorddy N</creatorcontrib><creatorcontrib>Santos, Cleydson B. R</creatorcontrib><creatorcontrib>Kimani, Njogu M</creatorcontrib><collection>Gale In Context: Opposing Viewpoints</collection><collection>Gale In Context: Science</collection><jtitle>PloS one</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ndarawit, Wilberforce</au><au>Ochieng, Charles Otieno</au><au>Angwenyi, David</au><au>Cruz, Jorddy N</au><au>Santos, Cleydson B. R</au><au>Kimani, Njogu M</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Discovery of [alpha]-amylase and [alpha]-glucosidase dual inhibitors from NPASS database for management of Type 2 Diabetes Mellitus: A chemoinformatic approach</atitle><jtitle>PloS one</jtitle><date>2024-11-14</date><risdate>2024</risdate><volume>19</volume><issue>11</issue><spage>e0313758</spage><pages>e0313758-</pages><issn>1932-6203</issn><eissn>1932-6203</eissn><abstract>Postprandial hyperglycemia, typical manifestation of Type 2 Diabetes Mellitus (T.sub.2 DM), is associated with notable global morbidity and mortality. Preventing the advancement of this condition by delaying the rate of glucose absorption through inhibition of [alpha]-amylase and [alpha]-glucosidase enzymatic activities is of utmost importance. Finding a safe antidiabetic drug is essential since those that are currently on the market have drawbacks like unpleasant side effects. The current study utilized computer-aided drug design (CADD), as a quick and affordable method to find a substitute drug template that can be used to control postprandial hyperglycemia by modulating the activity of [alpha]-amylase and [alpha]-glucosidase enzymes. The Natural Products Activity and Species database (NPASS) (30,926 compounds) was screened in silico, with a focus on evaluating drug-likeness, toxicity profiles and ability to bind on a target protein. Two molecules NPC204580 (Chrotacumine C) and NPC137813 (1-O-(2-Methoxy-4-Acetylphenyl)-6-O-(E-Cinnamoyl)-Beta-D-Glucopyranoside) were identified as potential dual inhibitors for [alpha]-amylase and [alpha]-glucosidase with free binding energies of -14.46 kcal/mol and -12.58 kcal/mol for [alpha]-amylase, and -8.42 kcal/mol and -8.76 kcal/mol for [alpha]-glucosidase, respectively. The molecules showed ionic, H-bonding and hydrophobic interactions with critical amino acid residues of both enzymes. Moreover, 100 ns molecular dynamic simulations showed that both molecules are stable on the receptors' active sites based on root mean square deviation (RMSD), root mean square fluctuation (RMSF), and the Generalized Born surface area (GBSA) energy calculated. The two compounds are thus promising therapeutic agents for T.sub.2 DM that merit further investigation due to their excellent binding energies, encouraging pharmacokinetics, toxicity profiles, and stability as demonstrated in simulated studies.</abstract><pub>Public Library of Science</pub><doi>10.1371/journal.pone.0313758</doi><tpages>e0313758</tpages></addata></record>
fulltext fulltext
identifier ISSN: 1932-6203
ispartof PloS one, 2024-11, Vol.19 (11), p.e0313758
issn 1932-6203
1932-6203
language eng
recordid cdi_gale_infotracmisc_A816058701
source DOAJ Directory of Open Access Journals; EZB-FREE-00999 freely available EZB journals; PubMed Central; Free Full-Text Journals in Chemistry; Public Library of Science (PLoS)
subjects Amino acids
Amylases
Biological products
Care and treatment
Dextrose
Diabetes therapy
Diagnosis
Force and energy
Glucose
Health aspects
Hydrogen bonding
Hyperglycemia
Molecular dynamics
Properties
Protein binding
Type 2 diabetes
title Discovery of [alpha]-amylase and [alpha]-glucosidase dual inhibitors from NPASS database for management of Type 2 Diabetes Mellitus: A chemoinformatic approach
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-04T21%3A45%3A33IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Discovery%20of%20%5Balpha%5D-amylase%20and%20%5Balpha%5D-glucosidase%20dual%20inhibitors%20from%20NPASS%20database%20for%20management%20of%20Type%202%20Diabetes%20Mellitus:%20A%20chemoinformatic%20approach&rft.jtitle=PloS%20one&rft.au=Ndarawit,%20Wilberforce&rft.date=2024-11-14&rft.volume=19&rft.issue=11&rft.spage=e0313758&rft.pages=e0313758-&rft.issn=1932-6203&rft.eissn=1932-6203&rft_id=info:doi/10.1371/journal.pone.0313758&rft_dat=%3Cgale%3EA816058701%3C/gale%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rft_galeid=A816058701&rfr_iscdi=true